Abstract
5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antimetabolites, Antineoplastic / pharmacology*
-
Biomarkers
-
Dihydrouracil Dehydrogenase (NADP)
-
Fluorouracil / pharmacology*
-
Fluorouracil / therapeutic use
-
Humans
-
Interferons / pharmacology
-
Microsatellite Repeats
-
Oligonucleotide Array Sequence Analysis
-
Oxidoreductases / antagonists & inhibitors
-
RNA / metabolism
-
Thymidine Phosphorylase / genetics
-
Thymidylate Synthase / genetics
-
Tumor Suppressor Protein p53 / physiology
Substances
-
Antimetabolites, Antineoplastic
-
Biomarkers
-
Tumor Suppressor Protein p53
-
RNA
-
Interferons
-
Oxidoreductases
-
Dihydrouracil Dehydrogenase (NADP)
-
Thymidylate Synthase
-
Thymidine Phosphorylase
-
Fluorouracil